392 results on '"Lee, Dung-Fang"'
Search Results
2. Structural basis of the human transcriptional Mediator regulated by its dissociable kinase module
3. Systematic transcriptome profiling of hPSC-derived osteoblasts unveils CORIN's mastery in governing osteogenesis through CEBPD modulation
4. Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation
5. Decoding the molecular symphony: interactions between the m6A and p53 signaling pathways in cancer.
6. Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy
7. List of contributors
8. Progress and possibilities for patient-derived iPSCs and genetically engineered stem cells in cancer modeling and targeted therapies
9. RNA m6A modification orchestrates a LINE-1–host interaction that facilitates retrotransposition and contributes to long gene vulnerability
10. Modeling of osteosarcoma with induced pluripotent stem cells
11. ZFP207 sustains pluripotency by coordinating OCT4 stability, alternative splicing and RNA export
12. Coordination of m6A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming
13. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling
14. Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.
15. Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism
16. Engineering Mutation Clones in Mammalian Cells with CRISPR/Cas9
17. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers
18. Wearable Biosensor with Molecularly Imprinted Conductive Polymer Structure to Detect Lentivirus in Aerosol
19. Osteosarcoma: Molecular Pathogenesis and iPSC Modeling
20. Unique transcriptional profiles underlie osteosarcomagenesis driven by different p53 mutants
21. Supplementary Figures from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
22. Supplementary Data 4 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
23. Supplementary Data 6 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
24. Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
25. Supplementary Data 5 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
26. Supplementary Data 3 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
27. Supplementary Data 1 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
28. Supplementary Table 1 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
29. Supplementary Table 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
30. Data from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
31. Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
32. Abstract LB361: Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death
33. Abstract LB169: Machine learning-based approach for glioblastoma drug repurposing on real-world patient data
34. Data from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
35. Supplementary Figures 1-4 from FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization
36. Data from Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
37. Data from FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization
38. Supplementary Materials and Methods from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
39. Supplementary Figure 3 from Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
40. Supplementary Figure Legends from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
41. Supplementary Figure Legends 1-4 from FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization
42. Supplementary Figure 2 from Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
43. Supplementary Figure 1 from Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
44. Supplementary Tables and Figures from AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
45. Modeling Cancer with Pluripotent Stem Cells
46. Reprogramming Stars #10: Modeling Cancer with Cellular Reprogramming—An Interview with Dr. Dung-Fang Lee
47. Bcl11b and Atoh8 Coordinate Cellular Plasticity for Reprogramming and Transformation
48. Generation of a homozygous knock-in human embryonic stem cell line expressing mEos4b-tagged CTR1
49. METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma
50. Abstract 1616: Dissecting the biology and therapeutic vulnerabilities of RB1-mutant osteosarcoma using hereditary retinoblastoma iPSCs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.